Literature DB >> 29487977

Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status.

M Unterrainer1, I Winkelmann1, B Suchorska2, A Giese3, V Wenter1, F W Kreth2, J Herms3, P Bartenstein1,4, J C Tonn2,4, N L Albert5,6.   

Abstract

PURPOSE: For the clinical evaluation of O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET images, the use of standard summation images obtained 20-40 min after injection is recommended. However, early summation images obtained 5-15 min after injection have been reported to allow better differentiation between low-grade glioma (LGG) and high-grade glioma (HGG) by capturing the early 18F-FET uptake peak specific for HGG. We compared early and standard summation images with regard to delineation of the PET-derived biological tumour volume (BTV) in correlation with the molecular genetic profile according the updated 2016 WHO classification.
METHODS: The analysis included 245 patients with newly diagnosed, histologically verified glioma and a positive 18F-FET PET scan prior to any further treatment. BTVs were delineated during the early 5-15 min and standard 20-40 min time frames using a threshold of 1.6 × background activity and were compared intraindividually. Volume differences between early and late summation images of >20% were considered significant and were correlated with WHO grade and the molecular genetic profile (IDH mutation and 1p/19q codeletion status).
RESULTS: In 52.2% of the patients (128/245), a significant difference in BTV of >20% between early and standard summation images was found. While 44.3% of WHO grade II gliomas (31 of 70) showed a significantly smaller BTV in the early summation images, 35.0% of WHO grade III gliomas (28/80) and 37.9% of WHO grade IV gliomas (36/95) had a significantly larger BTVs. Among IDH-wildtype gliomas, an even higher portion (44.4%, 67/151) showed significantly larger BTVs in the early summation images, which was observed in 5.3% (5/94) of IDH-mutant gliomas only: most of the latter had significantly smaller BTVs in the early summation images, i.e. 51.2% of IDH-mutant gliomas without 1p/19q codeletion (21/41) and 39.6% with 1p/19q codeletion (21/53).
CONCLUSION: BTVs delineated in early and standard summation images differed significantly in more than half of gliomas. While the standard summation images seem appropriate for delineation of LGG as well as IDH-mutant gliomas, a remarkably high percentage of HGG and, particularly, IDH-wildtype gliomas were depicted with significantly larger volumes in early summation images. This finding might be of interest for optimization of treatment planning (e.g. radiotherapy) in accordance with the individual IDH mutation status.

Entities:  

Keywords:  1p/19q codeletion; BTV; FET PET; Glioma; IDH

Mesh:

Year:  2018        PMID: 29487977     DOI: 10.1007/s00259-018-3969-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

Authors:  T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

2.  Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.

Authors:  Philipp Lohmann; Hans Herzog; Elena Rota Kops; Gabriele Stoffels; Natalie Judov; Christian Filss; Norbert Galldiks; Lutz Tellmann; Carolin Weiss; Michael Sabel; Heinz Hubert Coenen; Nadim Jon Shah; Karl-Josef Langen
Journal:  Eur Radiol       Date:  2015-03-27       Impact factor: 5.315

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  FET-PET for malignant glioma treatment planning.

Authors:  Maximilian Niyazi; Julia Geisler; Axel Siefert; Silke Birgit Schwarz; Ute Ganswindt; Sylvia Garny; Oliver Schnell; Bogdana Suchorska; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère; Claus Belka
Journal:  Radiother Oncol       Date:  2011-03-30       Impact factor: 6.280

5.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.

Authors:  Adriana Olar; Khalida M Wani; Kristin D Alfaro-Munoz; Lindsey E Heathcock; Hinke F van Thuijl; Mark R Gilbert; Terri S Armstrong; Erik P Sulman; Daniel P Cahill; Elizabeth Vera-Bolanos; Ying Yuan; Jaap C Reijneveld; Bauke Ylstra; Pieter Wesseling; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2015-02-21       Impact factor: 17.088

6.  Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.

Authors:  Niklas Thon; Sabina Eigenbrod; Eva M Grasbon-Frodl; Michael Ruiter; Jan H Mehrkens; Simone Kreth; Jörg C Tonn; Hans A Kretzschmar; Friedrich W Kreth
Journal:  J Neuropathol Exp Neurol       Date:  2009-11       Impact factor: 3.685

7.  Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study.

Authors:  Maciej Harat; Bogdan Małkowski; Roman Makarewicz
Journal:  Radiother Oncol       Date:  2016-07-01       Impact factor: 6.280

8.  Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Authors:  Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Sabina Eigenbrod; Christine Schmid-Tannwald; Andreas Zwergal; Maximilian Niyazi; Mark Drexler; Peter Bartenstein; Oliver Schnell; Jörg-Christian Tonn; Niklas Thon; Friedrich-Wilhelm Kreth; Christian la Fougère
Journal:  J Nucl Med       Date:  2013-12-30       Impact factor: 10.057

9.  Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Gabriele Stoffels; Cengiz Demirel; Charbel Attieh; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-11-23       Impact factor: 3.481

10.  Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Authors:  Pei Yang; Jinquan Cai; Wei Yan; Wei Zhang; Yinyan Wang; Baoshi Chen; Guilin Li; Shouwei Li; Chenxing Wu; Kun Yao; Wenbin Li; Xiaoxia Peng; Yongping You; Ling Chen; Chuanlu Jiang; Xiaoguang Qiu; Tao Jiang
Journal:  Neuro Oncol       Date:  2016-03-07       Impact factor: 13.029

View more
  9 in total

1.  TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study.

Authors:  M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-05       Impact factor: 9.236

2.  FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.

Authors:  Philipp Lohmann; Pantelis Stavrinou; Katharina Lipke; Elena K Bauer; Garry Ceccon; Jan-Michael Werner; Bernd Neumaier; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-16       Impact factor: 9.236

3.  Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study.

Authors:  Aliaksandra Shymanskaya; Wieland A Worthoff; Gabriele Stoffels; Johannes Lindemeyer; Bernd Neumaier; Philipp Lohmann; Norbert Galldiks; Karl-Josef Langen; N Jon Shah
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

4.  Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study.

Authors:  Marcus Unterrainer; D F Fleischmann; C Diekmann; L Vomacka; S Lindner; F Vettermann; M Brendel; V Wenter; B Ertl-Wagner; J Herms; C Wetzel; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-22       Impact factor: 9.236

Review 5.  Approaches to PET Imaging of Glioblastoma.

Authors:  Lindsey R Drake; Ansel T Hillmer; Zhengxin Cai
Journal:  Molecules       Date:  2020-01-28       Impact factor: 4.411

6.  Prediction of IDH Status Through MRI Features and Enlightened Reflection on the Delineation of Target Volume in Low-Grade Gliomas.

Authors:  Haixia Ding; Yong Huang; Zhiqiang Li; Sirui Li; Qiongrong Chen; Conghua Xie; Yahua Zhong
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

7.  The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.

Authors:  Feng-Min Liu; Yu-Fei Gao; Yanyan Kong; Yihui Guan; Jinsen Zhang; Shuai-Hong Li; Dan Ye; Wenyu Wen; Chuantao Zuo; Wei Hua
Journal:  BMC Cancer       Date:  2021-01-20       Impact factor: 4.430

8.  Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation.

Authors:  Lena Vomacka; Marcus Unterrainer; Adrien Holzgreve; Erik Mille; Astrid Gosewisch; Julia Brosch; Sibylle Ziegler; Bogdana Suchorska; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Peter Bartenstein; Nathalie Lisa Albert; Guido Böning
Journal:  EJNMMI Res       Date:  2018-09-10       Impact factor: 3.138

9.  Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.

Authors:  Hiroyuki Tatekawa; Akifumi Hagiwara; Hiroyuki Uetani; Shadfar Bahri; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson
Journal:  Cancer Imaging       Date:  2021-03-10       Impact factor: 3.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.